NovaBridge Biosciences

What NovaBridge Biosciences does

NovaBridge Biosciences (NASDAQ: NBP), formerly I-Mab Biopharma, is a clinical-stage biopharmaceutical company founded in 2016 and headquartered in Rockville, Maryland, that operates a Hub-and-Spoke platform dedicated to bringing Asian innovative medicines to global markets. The company is backed by CBC Group (formerly C-Bridge Capital), Asia's largest healthcare-dedicated asset management firm, whose CEO Fu Wei serves as Executive Chairman. As of December 31, 2025, NovaBridge held $210.8 million in cash supporting operations through 2028 and reported a FY2025 net loss of $88.3 million, with no approved products or commercial revenue.

The company's pipeline is built on proprietary bispecific antibody platform technology spanning immuno-oncology and ophthalmology. Lead oncology asset givastomig is a CLDN18.2 x 4-1BB bispecific antibody with silenced FC (IgG1) for conditional T cell activation, targeting first-line HER2-negative metastatic gastric cancer; it holds FDA Fast Track Designation, FDA-confirmed accelerated approval pathway eligibility, and FDA Orphan Drug Designation, with a registrational Phase 3 trial planned for Q4 2026. Additional oncology assets include ragistomig (PD-L1 x 4-1BB bispecific, developed with ABL Bio's Grabody-T platform) and uliledlimab (anti-CD73 monoclonal antibody). In ophthalmology, subsidiary Visara, Inc. is advancing VIS-101, a tetravalent VEGF-A x ANG-2 bispecific antibody for wet AMD, DME, and RVO, with Phase 2a data showing >10 ETDRS letters visual acuity improvement and approximately 50% of patients retreatment-free at six months.

NovaBridge is pre-revenue and expects future revenue from pharmaceutical product sales upon regulatory approval, distributed through specialty pharmacy and hospital channels. The company is preparing commercial capabilities through the appointment of a President and Chief Commercial Officer (Mark Hagler, April 2026) and a new CEO (Dr. Srishti Gupta, July 2026) with prior operational turnaround experience at Idorsia Ltd. The company maintains operational offices in the US (Rockville, Needham, Short Hills) and Asia (Hong Kong, Shanghai), and co-develops assets with strategic partners ABL Bio and Everest Medicines.

Name

NovaBridge Biosciences

Legal name

NovaBridge Biosciences

Website

https://novabridge.com

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

NovaBridge Biosciences is a clinical-stage biopharmaceutical company operating a Hub-and-Spoke platform to develop and globalize bispecific antibody therapeutics in immuno-oncology (givastomig, ragistomig, uliledlimab) and ophthalmology (VIS-101), serving patients with gastric cancer and retinal vascular diseases.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biopharmaceuticals

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), Gastroenterology Specialty Pharmaceuticals (HLAIACAE), Oncology & Hematology Pharmaceuticals (HLAIAAAC)

Keywords

• Bispecific antibody therapeutics
• Immuno-oncology drug development
• Clinical-stage biopharmaceuticals
• Ophthalmic biologics
• Oncology pipeline drugs

Headquarters

HQ city

Rockville

HQ country

United States

HQ region

North America

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical Product Revenue: NovaBridge is a pre-revenue clinical-stage biopharmaceutical company. The company expects to generate revenue from sales of approved drug candidates, primarily givastomig for gastric cancer and VIS-101 for wet AMD, once regulatory approvals are obtained. The company maintains $210.8M in cash as of December 31, 2025, providing runway through 2028.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

NovaBridge Biosciences is a clinical-stage biopharmaceutical company developing bispecific antibody therapeutics for oncology and ophthalmology indications. The company's pipeline includes givastomig (CLDN18.2 x 4-1BB bispecific antibody) for first-line HER2-negative metastatic gastric cancer, VIS-101 (VEGF-A x ANG-2 bispecific antibody) for retinal vascular diseases, ragistomig (PD-L1 x 4-1BB), and uliledlimab (anti-CD73 mAb). The company operates a Hub-and-Spoke platform linking Asian innovative medicines to global markets, backed by CBC Group.

Differentiator

Problem solved

Functional benefit

Products and services

• Givastomig A Claudin 18.2 x 4-1BB bispecific antibody that conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Features silenced FC (IgG1) to minimize unintended systemic immune activation and conditional 4-1BB agonist activity for localized T cell activation. In development for HER2-negative, CLDN18.2+, PD-L1+ metastatic gastric/gastroesophageal adenocarcinoma in combination with nivolumab and chemotherapy. Demonstrated 75% objective response rate and 16.9-month median progression-free survival in Phase 1b trials. Received FDA Fast Track Designation and FDA Orphan Drug Designation.
• VIS-101 A tetravalent dual VEGF-A x ANG-2 bispecific antibody designed for retinal vascular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Features humanized anti-VEGF-A mAb with approximately 2X inhibitory activity, optimized Fc region for shortened plasma half-life, and anti-Ang-2 inhibitory peptides (18mers) with approximately 17X inhibitory activity for class-leading durability. Achieved >10 ETDRS letters mean visual acuity improvement in Phase 2a wet AMD study, with approximately half of patients remaining retreatment-free at six months. Developed under the Visara, Inc. subsidiary.
• Ragistomig A PD-L1 x 4-1BB bispecific antibody using ABL Bio's 'Grabody-T' platform. Uses the PD-L1 arm as tumor-dependent T-cell activator and the 4-1BB arm as conditional T cell activator upon tumor engagement, stimulating 4-1BB activation only in the presence of PD-L1 expressing tumor cells to minimize off-tumor toxicity. In development for solid tumors including non-small cell lung cancer in combination with PD-(L)1 inhibitors. Being jointly developed through a global partnership with ABL Bio.
• Uliledlimab A differentiated, humanized anti-CD73 monoclonal antibody that targets the CD73 ecto-enzyme which converts extracellular AMP to adenosine in the tumor microenvironment. Features a unique intra-dimer binding mechanism leading to differentiated and favorable functional properties for suppressing tumor growth in combination with checkpoint therapies. Developed for solid tumors with adenosine-driven immunosuppression.

Quantifiable outcome

• 75% objective response rate and 16.9-month median progression-free survival in Phase 1b givastomig study
• +2 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core, major and minor.

• ABL BiocoreStrategic or Co-development PartnerABL Bio is a global biotechnology company and key development partner for givastomig (ABL111) and ragistomig (ABL503). Givastomig is being jointly developed through a global partnership with ABL Bio, where NovaBridge is the lead party and shares worldwide rights excluding Greater China and South Korea equally with ABL Bio. Ragistomig (TJ-L14B/ABL503) uses ABL Bio's 'Grabody-T' bispecific antibody platform technology.
• Everest MedicinesmajorStrategic or Co-development PartnerEverest Medicines holds regional rights to VIS-101 in Greater China and certain Asian territories. Visara (NovaBridge majority-owned subsidiary) grants Everest Medicines exclusive license for development and commercialization of VIS-101 outside NovaBridge's retained territories.
• ABio-X HoldingsminorStrategic or Co-development PartnerABio-X is shown as a partner logo on NovaBridge's website. Dr. Sean Cao co-founded ABio-X Holdings and serves as director.
• TJ BiopharmaminorStrategic or Co-development PartnerTJ Biopharma is shown as a partner logo on NovaBridge's website. Chun Kwok Alan Au serves as independent non-executive director of TJ Biopharma since January 2021.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Zymeworks: Clinical-stage biotech with proprietary bispecific antibody platforms (Aziyo and EFECT) used to develop oncology candidates. Highly comparable to NovaBridge's platform-based approach to building a multi-asset bispecific pipeline.
• Genmab: Industry leader in bispecific antibody technology (Duobody platform) and developer of multiple approved and clinical-stage bispecifics in oncology. Comparable to NovaBridge as a developer of differentiated bispecific antibody therapeutics targeting immuno-oncology indications.
• Akeso: China-headquartered clinical-stage bispecific antibody developer with multiple oncology assets (e.g., ivonescimab, cadonilimab) and a similar Asia-origin model of advancing innovative biologics globally. Strong overlap with NovaBridge's oncology bispecific strategy and Asian biotech positioning.
• ABL Bio: South Korea-based clinical-stage biotech developing bispecific antibodies using the Grabody-T platform, which is the same technology underlying NovaBridge's givastomig and ragistomig. ABL Bio is a co-development partner and most directly comparable peer in bispecific antibody design and pipeline.
• MacroGenics: Clinical-stage oncology biotech developing bispecific antibodies (e.g., DART and TRIDENT platforms) for solid tumors, including PD-L1 x 4-1BB and other immuno-oncology targets that overlap with NovaBridge's ragistomig and givastomig mechanisms.

Broad incumbents

• Regeneron Pharmaceuticals: Broad biopharmaceutical incumbent and the dominant competitor in retinal vascular disease treatment with Eylea/Eylea HD in the wet AMD/DME market where NovaBridge's VIS-101 will compete. Includes Regeneron to frame VIS-101's competitive landscape.

Regional players

• Everest Medicines: Asia-region-focused clinical and commercial biopharma with regional rights to NovaBridge's VIS-101 (VEGF-A x ANG-2) for Greater China and selected Asian territories. Operates a similar model of bringing innovative therapeutics into the Asia-Pacific market.

Emerging players

• Compass Therapeutics: Clinical-stage oncology biotech developing bispecific antibodies (e.g., CTX-009, CTX-112) with checkpoint and tumor-targeted mechanisms comparable to NovaBridge's 4-1BB-based bispecifics. Similar early-stage platform with multiple oncology indications.
• Cullinan Oncology: Clinical-stage oncology biotech developing multiple targeted therapies (including CLDN18.2 and immuno-oncology assets) with a hub-style pipeline approach similar to NovaBridge's structure. Comparable as a multi-asset oncology biotech.
• Adagene: Clinical-stage biotech with POWERbody masked antibody platform developing bispecifics and ADCs for oncology, with a comparable China-Asia origin and clinical-stage profile. Overlaps with NovaBridge's approach to engineering differentiated antibody formats.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/novabridge-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NovaBridge Biosciences